---
document_datetime: 2024-11-26 16:43:25
document_pages: 16
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/opsumit-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: opsumit-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.9176217
conversion_datetime: 2025-12-26 12:18:25.882807
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Opsumit

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                 |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------|
| IB/0054              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 11/10/2024                          | n/a                                         |                                  |                                                                         |
| X/0051/G             | This was an application for a group of variations.                                                                                            | 25/07/2024                          | 19/09/2024                                  | SmPC, Labelling and              | Please refer to the Assessment Report Opsumit EMEA-H-C- 002697-X-0051-G |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Extension application to pharmaceutical form associated (2.5 mg dispersible tablet) extension of indication (C.I.6.a) monotherapy or in combination, treatment of pulmonary in paediatric patients aged years of age of WHO Functional for OPSUMIT. In addition, coated tablet is extended, combination, for the long-term paediatric patients aged bodyweight ≥ 40 kg with II to III. This is based on with exposure matching range given the similarity and adults, as well as on safety data from the phase (TOMORROW). TOMORROW label, randomized study period to assess the pharmacokinetics, efficacy of macitentan versus children with pulmonary As a consequence, sections 5.1 and 5.2 of the SmPC are updated. The Package updated in accordance. also been submitted. Annex I_2.(c) Change or strength/potency   | PL   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|

<div style=\"page-break-after: always\"></div>

|                     | pharmaceutical form C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10115 /202310 | Periodic Safety Update EU Single assessment - macitentan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 13/06/2024 | n/a | PRAC Recommendation - maintenance |
| IB/0052/G           | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 21/12/2023 | n/a |                                   |
| IA/0050             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 24/04/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0049   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                               | 27/03/2023   | n/a        |             |                                                                                                                                                                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0047   | Update of section 4.8 of the SmPC in order to add 'flushing' to the list of adverse drug reactions (ADRs) with frequency 'common' based on a cumulative review of cases (post-marketing, clinical studies, registry) and literature; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 01/12/2022   | 29/06/2023 | SmPC and PL |                                                                                                                                                                       |
| IA/0048   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                             | 25/10/2022   | n/a        |             |                                                                                                                                                                       |
| II/0046   | Update of sections 4.6 and 5.3 of the SmPC in order to introduce additional data on male fertility based on literature search and global safety database. The RMP version 13.1 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                | 10/06/2022   | 29/06/2023 | SmPC        | SmPC new text Decreases in sperm count have been observed in patients taking ERAs. Macitentan, like other ERAs, may have an adverse effect on spermatogenesis in men. |

<div style=\"page-break-after: always\"></div>

| II/0043   | Update of sections 4.2 and 4.4 of the SmPC to                                                                                                            | 28/04/2022   | 29/06/2023   | SmPC and PL            | Opus Registry (AC-055-503) is a multicenter, prospective,   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-------------------------------------------------------------|
| II/0042   | Update of the Risk management plan to v12.2 and consequential update of the Annex II and the patient alert card in the labelling based on the outcome of | 10/02/2022   | 05/05/2022   | Annex II and Labelling | n/a                                                         |

<div style=\"page-break-after: always\"></div>

|         | the PRAC assessment of EMEA/H/C/PSUSA/00010115/202010 : - The controlled distribution system and Prescriber Kit (SmPC, prescribing check list and HCP brochure) is being removed as additional risk minimization measures (aRMM) in the RMP and in the product information Annex II.D. Only the patient card is remaining as an aRMM. - Off-label use is being removed from the list of safety concerns. - 'Elderly patients aged over 75 years', \"Patients with moderate to severe hepatic impairment' and 'Patients with severe renal impairment and/ or undergoing dialysis' are being removed as missing information. - The MAH has also taken the opportunity to include in the RMP Annex 4, the updated Specific Follow-up Questionnaires Forms (pregnancies, menstrual disorders, and ovarian cysts) due to revision of internal company template. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH   |            |            |      |                                                                                                                                                                                                                           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0044 | Update of SmPC sections 4.8 and 5.1, based on the long-term follow-up data from SERAPHIN open-label (OL) study. SERAPHIN OL study was a long-term single-arm open-label extension study of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13/01/2022 | 05/05/2022 | SmPC | Of the 742 patients who participated in the pivotal SERAPHIN double-blind study, 550 patients entered a long- term open-label (OL) extension study. The OL cohort included 182 patients who continued on macitentan 10 mg |

<div style=\"page-break-after: always\"></div>

|                     | SERAPHIN double-blind (DB) study, to assess the safety and tolerability of macitentan in patients with symptomatic pulmonary arterial hypertension (PAH) that have completed the DB study or that experienced a morbidity event and for who a written approval to roll over into the OL study was obtained by the sponsor. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                             |            |     | and 368 patients who received placebo or macitentan 3 mg and crossed over to macitentan 10 mg. Long-term follow- up of these 550 patients for a median exposure of 3.3 years and a maximum exposure of 10.9 years showed a safety profile that was consistent as during the SERAPHIN double-blind phase. In long-term follow-up of 242 patients who were treated with macitentan 10 mg in the double-blind (DB) phase of the SERAPHIN study, 182 of which continued with macitentan in the open-label (OL) extension study (SERAPHIN OL) (DB/OL cohort) , Kaplan-Meier estimates of survival at 1, 2, 5, 7 and 9 years were 95%, 89%, 73%, 63% and 53%, respectively. The median follow-up time was 5.9 years.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0045/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation A.7 - Administrative change - Deletion of | 06/12/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10115 /202010 | Periodic Safety Update EU Single assessment - macitentan                                                                                                                                                                                                                                                                                                                                                                                                                                 | 10/06/2021 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| II/0039   | Update of sections 4.4, 4.5, and 5.2 of the SmPC in order to add drug-drug interaction information of macitentan with moderate dual inhibitors of CYP3A4 and CYP2C9 based on results from a non-clnical study and a physiologically based pharmacokinetic study in healthy subjects and CYP2C9 poor metabolizers; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to make editorial changes in the labelling. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 22/04/2021   | 05/05/2022   | SmPC, Labelling and PL           | The cytochrome P450 CYP3A4 is the main enzyme involved in the metabolism of macitentan and in the formation of its active metabolite, with minor contribution from CYP2C8, CYP2C9, and CYP2C19 enzymes. Caution should be exercised when macitentan is administered concomitantly with moderate dual inhibitors of CYP3A4 and CYP2C9 (e.g., fluconazole and amiodarone). In the presence of fluconazole 400 mg daily, a moderate dual inhibitor of CYP3A4 and CYP2C9, exposure to macitentan may increase approximately 3.8-fold based on PBPK modelling. However, there was no clinically relevant change in exposure to the active metabolite of macitentan. The uncertainties of such modelling should be considered. Caution should also be exercised when macitentan is administered concomitantly with both a moderate CYP3A4 inhibitor (e.g., ciprofloxacin, cyclosporine, diltiazem, erythromycin, verapamil) and moderate CYP2C9 inhibitor (e.g., miconazole, piperine).   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0041/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging                                                                                                                           | 12/03/2021   | 05/05/2022   | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           | or pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |      |                                                                                                                                                                     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0038/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 15/06/2020 | n/a        |      |                                                                                                                                                                     |
| IB/0037   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                 | 04/06/2020 | n/a        |      |                                                                                                                                                                     |
| II/0035/G | This was an application for a group of variations. Update of section 4.5 of the SmPC in order to update the drug-drug interaction information of macitentan with Breast cancer resistance protein (BCRP) substrate drugs based on final results from studies AC-055-122 and AC-055-123 ; these are single- center, open-label, one-sequence, two- treatment studies investigating the effect of macitentan at steady state on the pharmacokinetics of rosuvastatin                                                                                                            | 17/04/2020 | 17/02/2021 | SmPC | Macitentan 10 mg once daily did not affect the pharmacokinetics of Breast Cancer Resistance Protein (BCRP) substrate drugs (riociguat 1 mg and rosuvastatin 10 mg). |

<div style=\"page-break-after: always\"></div>

|                     | qnd riociguat respectively in healthy male subjects. In addition, a minor editorial change was introduced in Section 5.1. The MAH also took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                 |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IAIN/0036/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing            | 26/02/2020 | 17/02/2021 | Annex II and PL |                                   |
| N/0034              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                      | 24/09/2019 | 17/02/2021 | PL              |                                   |
| PSUSA/10115 /201810 | Periodic Safety Update EU Single assessment - macitentan                                                                                                                                                                                                                                                                                                                                                                                                              | 16/05/2019 | n/a        |                 | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0032             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                      | 30/11/2018   | n/a        |                        |                                                                                                                                                                                                                                                                       |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0031              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                         | 21/11/2018   | 17/02/2021 | PL                     |                                                                                                                                                                                                                                                                       |
| IA/0030             | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                      | 14/11/2018   | n/a        |                        |                                                                                                                                                                                                                                                                       |
| T/0028              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                      | 23/08/2018   | 21/09/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                       |
| R/0027              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                  | 28/06/2018   | 23/08/2018 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Opsumit in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10115 /201710 | Periodic Safety Update EU Single assessment - macitentan                                                                                                                                                                                                                                 | 17/05/2018   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| II/0025/G           | This was an application for a group of variations. B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings B.II.b.1.c - Replacement or addition of a | 18/01/2018   | 23/08/2018 | SmPC, Annex II and PL  |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                     | manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0024             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                              | 26/07/2017 | n/a |                                   |
| IB/0023/G           | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                            | 22/05/2017 | n/a |                                   |
| PSUSA/10115 /201610 | Periodic Safety Update EU Single assessment - macitentan                                                                                                                                                                                                                                                                                                                                                                                                                                          | 05/05/2017 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0021             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                    | 10/01/2017   | 17/07/2017   | SmPC, Annex II and Labelling   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------------|
| IB/0020             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                       | 14/12/2016   | n/a          |                                |
| PSUSA/10115 /201604 | Periodic Safety Update EU Single assessment - macitentan                                                                                                                                                                                     | 27/10/2016   | n/a          |                                |
| IG/0720             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing       | 16/08/2016   | 17/07/2017   | Annex II and PL                |
| PSUSA/10115 /201510 | Periodic Safety Update EU Single assessment - macitentan                                                                                                                                                                                     | 14/04/2016   | n/a          |                                |
| IA/0017             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 13/04/2016   | n/a          |                                |
| IA/0016             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                | 23/03/2016   | n/a          |                                |
| IB/0015             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale                                                                                                                                  | 04/03/2016   | 15/07/2016   | SmPC, Annex II, Labelling      |

<div style=\"page-break-after: always\"></div>

|                     | (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            | and PL          |                                                                                                                                             |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10115 /201504 | Periodic Safety Update EU Single assessment - macitentan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 06/11/2015 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                           |
| II/0007/G           | This was an application for a group of variations. Submission of studies AC-055C301/DUAL-1 and AC- 055C302/DUAL-2, two completed Phase 3 studies in patients with digital ulcers associated with systemic sclerosis. An updated RMP has been submitted accordingly (latest approved version is v.9.0). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 24/09/2015 | n/a        |                 |                                                                                                                                             |
| IG/0612             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                       | 07/09/2015 | 15/07/2016 | Annex II and PL |                                                                                                                                             |
| II/0008             | Update of section 4.5 of the SmPC in order to update the safety information on drug-drug interaction reporting no interaction between macitentan and hormonal contraceptives. Furthermore the MAH took the occasion to updated section 5.3 of the SmPC to introduce minor correction on two ratios revised                                                                                                                                                                                                                                                   | 06/08/2015 | 15/07/2016 | SmPC and PL     | Macitentan 10 mg once daily did not affect the pharmacokinetics of an oral contraceptive (norethisterone 1 mg and ethinyl estradiol 35 µg). |

<div style=\"page-break-after: always\"></div>

|                     | based on data already assessed during Marketing Authorisation Application. In addition the MAH took the opportunity to make some linguistic improvements and correct typographical errors to the Annexes in various languages (BG, CS, DA, DE, EL, ES, ET, FI, FR, HR, HU, IT, LT, LV, MT, PL, PT, RO, SK, SL, SV) and to update administrative information for its local representatives for Estonia, Ireland, Latvia, Lithuania, Malta and United Kingdom. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                        |                                                                                                                                                               |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10115 /201410 | Periodic Safety Update EU Single assessment - macitentan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/05/2015 | 28/07/2015 |                        | Please refer to Opsumit-PSUSA-00010115-201410 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IA/0009             | B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/06/2015 | n/a        |                        |                                                                                                                                                               |
| PSUV/0003           | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/11/2014 | 15/01/2015 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0003.                             |
| IA/0005             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 17/09/2014 | 15/01/2015 | SmPC, Labelling and PL |                                                                                                                                                               |
| IB/0002             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/07/2014 | n/a        |                        |                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| N/0001   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 28/05/2014   | 15/01/2015   | PL   |
|----------|----------------------------------------------------------------------------------------------------|--------------|--------------|------|